Research in Advanced Lung Diseases at Columbia University Medical Center

Overview and Mission

The Advanced Lung Disease Program at Columbia University Medical Center aims to offer new treatments to adults living with chronic lung diseases, including:

  • Pulmonary fibrosis
  • Chronic obstructive pulmonary disease
  • Bronchiectasis
  • Idiopathic Pulmonary Fibrosis
  • Interstitial Lung Disease
  • Primary Ciliary Dyskinesa 
  • Pulmonary M.A.C

We also investigate the causes and complications of these diseases in clinical, translational, and epidemiological studies funded by the National Institutes of Health (NIH), the Pulmonary Fibrosis Foundation, and others.

Additionally, we provide resources for physicians and researchers at Columbia University Medical Center who need support with clinical trial startup and management. Our research staff can assist investigators with study startup and management, IRB submissions and communication, conducting and scheduling research subject visits, and coordination with Columbia University Medical Center / New York Presbyterian Hospital recourses.

Ongoing Research Studies Open to Enrollment

Please call (212) 342-4167 if you are interested in participating in one of our research studies or if you would like to learn more about our research. Please note that we may be conducting additional studies that are not listed on our website.

Chronic Obstructive Pulmonary Disease (COPD)

Block-COPD
This study is examining whether a beta-blocker drug called metoprolol succinate can be used safely and effectively to reduce the frequency and severity of COPD exacerbations. This drug is already FDA-approved to treat cardiovascular disease, and this study will determine if this drug may also be able to help patients living with COPD.

PI: Keith Brenner, MD
Contact: M. Atif Choudhury (212) 342-1518 | mac2463@columbia.edu

Families At Risk Interstitial Lung Disease

FAR-ILD
The purpose of this study is to gain a better understanding of the cause of interstitial lung disease, including the use of genetic test. We are studying the results of the genetic test being performed to find and possibly confirm associations between interstitial lung disease and specific genes or genetic variants. Our overall goal is to conduct studies preparatory to and requisite for the testing of ILD Preventative interventions.

PI: David Lederer, MD
Contact: M. Atif Choudhury (212) 342-1518 | mac2463@columbia.edu

Hermansky-Pudlak Syndrome

The HPS Study
We are conducting an observational study of people who have Hermansky-Pudlak Syndrome (HPS), a rare genetic disorder that is associated with interstitial lung disease. The purpose of this study is to collect information on the factors that lead to lung scarring and dysfunction in people with HPS to aid the development of better treatments for this disease.

PI: David Lederer, MD, MS
Contact: Maahika Srinivasan | mks2217@columbia.edu   

Interstitial Lung Disease / Pulmonary Fibrosis

IPF-PRO Registry
We are collecting medical history and health information as a part of a registry of patients newly diagnosed with Idiopathic Pulmonary Fibrosis (IPF). We hope that this registry will help doctors understand how to improve the quality of care for people living with IPF. 

PI: David Lederer, MD, MS 
Contact: Maahika Srinivasan | mks2217@columbia.edu

Pulmonary Fibrosis Foundation Registry
We are collecting medical history and health information on patients with interstitial lung disease as a part of a registry sponsored by the Pulmonary Fibrosis Foundation. This registry will provide investigators with long-term data on the progression of interstitial lung disease and promote new research and innovation in the field.

PI: David Lederer, MD, MS
Contact: M. Atif Choudhury (212) 342-1518 | mac2463@columbia.edu

Scleroderma (Systemic Sclerosis) with Interstitial Lung Disease (Pulmonary Fibrosis)

Nintedanib for SSc-ILD
This study is a clinical trial examining whether nintedanib (Ofev®) – a drug currently FDA-approved for the treatment of Idiopathic Pulmonary Fibrosis (IPF) – can be safely and effectively used to treat Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD).

PI: Nina Patel, MD
Contact: Allison Wolf (212) 342-4412 | aw2565@columbia.edu

Primary Ciliary Dyskensia

Parion Clinical Study
The purpose of this study is to find out if you can take the prescribed dose of VX-371 without porblems, and weather VX-371 is safe and helps subjects with PCD.VX-371 is called an investigational or experimental drug because it has not been approved for use in people by the Food and Drug Administration (FDA), the branch of U.S. government which approves new drugs, or by any other regulatory agency in other countries. Inhaled HS is sometimes used to treat PCD patients. HS is extra-salty water that is sterile, so there are no germs in it. HS is also considered experimental in this study.

PI: Angela Dimango, MD
Contact: Tatiana Blue (212) 342-4167 | tjb2134@columbia.edu

Contact

If you are a patient and would like more information on participating in any of our ongoing clinical trials or if you are a Columbia investigator and would like to know how our team can help you launch and manage your study, please contact:

Tatiana Blue | tjb2134@columbia.edu
Columbia University Medical Center
622 W. 168th Street | PH9-215
Phone: (212) 342-4167 | Fax: (212) 342-4525